SAT0436 Durability of Apremilast Response in Patients With Psoriatic Arthritis: Long-Term (208-Week) Results From the Palace 1 Trial

doi 10.1136/annrheumdis-2017-eular.3001
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Longterm (52-Week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients With Psoriatic Arthritis

Journal of Rheumatology
RheumatologyAllergyImmunology
2015English

Therapeutic Benefit of Apremilast on Enthesitis and Dactylitis in Patients With Psoriatic Arthritis: A Pooled Analysis of the PALACE 1–3 Studies

RMD Open
RheumatologyAllergyImmunology
2018English

Work Productivity Improvement Associated With Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis Results of a Phase 3, Randomized, Controlled Trial

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Pss13 - Budget Impact Analysis of Apremilast in Patients With Active Psoriatic Arthritis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Long-Term Survival of Methotrexate in Psoriatic Arthritis

Reumatismo
Rheumatology
2011English

Cost Per Responder of Apremilast Versus Etanercept and Adalimumab in Patients With Active Psoriatic Arthritis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Improved Patient-Reported Outcomes in Patients With Psoriatic Arthritis Treated With Abatacept: Results From a Phase 3 Trial

Arthritis Research & Therapy
2018English

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis

Rheumatology and Therapy
2014English

Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Arthritis Care and Research
Rheumatology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy